1-Oleoyl Lysophosphatidic Acid
(Synonyms: 1-Oleoyl LPA, Oleoyl-sn-3-Glycerophosphate) 目录号 : GC42011A potent LPA receptor agonist
Cas No.:65528-98-5
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
1-Oleoyl lysophosphatidic acid is a species of lysophosphatidic acid (LPA) containing oleic acid at the sn-1 position. Phosphatidic acid is produced either directly through the action of phospholipase D (PLD) or through a two step process involving liberation of diacylglycerol (DAG) by phospholipase C (PLC) followed by phosphorylation of DAG by diglycerol kinase.[1] Hydrolysis of the fatty acid at the sn-2 position by phospholipase A2 (PLA2) yields bioactive LPA. LPA binds to one of five different G protein linked receptors to mediate a variety of biological responses including cell proliferation, smooth muscle contraction, platelet aggregation, neurite retraction, and cell motility.[2],[1] 1-Oleoyl lysophosphatidic acid is the most potent of the LPA analogs for calcium mobilization in A431 cells and for growth stimulation of a variety of cell lines.[3],[4]
1-油酰溶血磷脂酸是一种溶血磷脂酸 (LPA)，在 sn-1 位置含有油酸。磷脂酸是通过磷脂酶 D (PLD) 的作用直接产生的，或者是通过磷脂酶 C (PLC) 释放二酰甘油 (DAG) 然后通过双甘油激酶对 DAG 进行磷酸化的两步过程产生的。 [1]磷脂酶 A2 (PLA2) 水解 sn-2 位的脂肪酸产生具有生物活性的 LPA。 LPA 与五种不同的 G 蛋白连接受体之一结合，介导多种生物反应，包括细胞增殖、平滑肌收缩、血小板聚集、神经突收缩和细胞运动。[2]、[1] 1-油酰溶血磷脂酸是LPA 类似物中最有效的 A431 细胞钙动员和多种细胞系的生长刺激。[3],[4]
Reference:
[1]. Moolenaar, W.H. LPA: A novel lipid mediator with diverse biological actions. Trends in Cell Biology 4, 213-219 (1994).
[2]. Noguchi, K., Ishii, S., and Shimizu, T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. The Journal of Biological Chemisty 278(28), 25600-25606 (2003).
[3]. Jalink, K., Hengeveld, T., Mulder, S., et al. Lysophosphatidic acid-induced Ca2+ mobilization in human A4431 cells: Structure-activity analysis. Biochemistry Journal 307, 609-616 (1995).
[4]. van Corven, E.J., van Rijswijk, A., Jalink, K., et al. Mitogenic action of lysophosphatidic acid and phosphatidic acid on fibroblasts. Dependence on acyl-chain length and inhibition by suramin. Biochemistry Journal 281, 163-169 (1992).
| Cas No. | 65528-98-5 | SDF | |
| 别名 | 1-Oleoyl LPA, Oleoyl-sn-3-Glycerophosphate | ||
| 化学名 | 1-O-9Z-octadecenoyl-sn-glyceryl-3-phosphoric acid | ||
| Canonical SMILES | CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)O | ||
| 分子式 | C21H41O7P | 分子量 | 436.5 |
| 溶解度 | DMF: 2 mg/ml; DMSO: 2.5 mg/ml; Ethanol: 25 mg/ml; PBS (pH 7.2): 3 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.291 mL | 11.4548 mL | 22.9095 mL |
| 5 mM | 0.4582 mL | 2.291 mL | 4.5819 mL |
| 10 mM | 0.2291 mL | 1.1455 mL | 2.291 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
1-Oleoyl Lysophosphatidic Acid: a new mediator of emotional behavior in rats
PLoS One 2014 Jan 7;9(1):e85348.PMID:24409327DOI:10.1371/journal.pone.0085348.
The role of lysophosphatidic acid (LPA) in the control of emotional behavior remains to be determined. We analyzed the effects of the central administration of 1-oleoyl-LPA (LPA 18∶1) in rats tested for food consumption and anxiety-like and depression-like behaviors. For this purpose, the elevated plus-maze, open field, Y maze, forced swimming and food intake tests were performed. In addition, c-Fos expression in the dorsal periaqueductal gray matter (DPAG) was also determined. The results revealed that the administration of LPA 18∶1 reduced the time in the open arms of the elevated plus-maze and induced hypolocomotion in the open field, suggesting an anxiogenic-like phenotype. Interestingly, these effects were present following LPA 18∶1 infusion under conditions of novelty but not under habituation conditions. In the forced swimming test, the administration of LPA 18∶1 dose-dependently increased depression-like behavior, as evaluated according to immobility time. LPA treatment induced no effects on feeding. However, the immunohistochemical analysis revealed that LPA 18∶1 increased c-Fos expression in the DPAG. The abundant expression of the LPA1 receptor, one of the main targets for LPA 18∶1, was detected in this brain area, which participates in the control of emotional behavior, using immunocytochemistry. These findings indicate that LPA is a relevant transmitter potentially involved in normal and pathological emotional responses, including anxiety and depression.